{"name":"Angitia Biopharmaceuticals","slug":"angitia-biopharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNQWo0Q0w4T1R4STJVZlh6cEdQVnJkV3gzbFJWcUE0RlQ2Q3N6QUFBVWVkQkExNGJtYTJtTGpvbWdwMTlKOVB1Wk9SSmU2MTdIdUFDYW9wSm5ISGJCbUJvU2VEbnV1REZDUE4yZEN2R25Dbko0MGszUzRLaWVIVzhXZmY0TnNrN0RPalByb2VVQ2Y3X1ZmNGRUazJmMEpFU2ZFQ1lkak9vN1FJN0xDWnpRZGJqWQ?oc=5","date":"2026-02-06","type":"trial","source":"Longevity.Technology","summary":"Angitia Bio lands $130m to advance human trials of musculoskeletal health drugs - Longevity.Technology","headline":"Angitia Bio lands $130m to advance human trials of musculoskeletal health drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE41bEFyQzZEdkU3cS1IQk1DN3E4aVpuOF9TMEZUWG1GVHp2aDIzZlJ3NVZHN195UkowXzJoX21hQW05ZzF5TzFZWWhZNk1ydDBJMlNB?oc=5","date":"2026-02-05","type":"deal","source":"FirstWord Pharma","summary":"Biopharma bites: Angitia, LB Pharma raise funds, plus Eisai-Henlius deal and CVS formulary updates - FirstWord Pharma","headline":"Biopharma bites: Angitia, LB Pharma raise funds, plus Eisai-Henlius deal and CVS formulary updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOcU9zYlBDZWJqTmlraDdhakJsdUJYc3J5VlAzMnhMMF9MQjZFNFhlaV9BRWZ4dkcxa3l4WFkxM1RFV1pXMTNac00wbVpnX2JXWml1blNlUWtDeHhDRTk5WjdKRlRWQ2JLUllZWmFjT1FITkxSSy1tWmtuSEZfM0Z1SlFqZDhudm9kTDBveUljWkI5SVc0LXNXd21KMlRJZDhw?oc=5","date":"2026-02-05","type":"pipeline","source":"Fierce Biotech","summary":"Angitia raises $130M to challenge Amgen with bone-building bispecifics - Fierce Biotech","headline":"Angitia raises $130M to challenge Amgen with bone-building bispecifics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxOSWpzRXhOUlZTRWN6VFRNZzNkSE5jaTF6cjE4UWpDR09lQ2NvWVhGMTRlVmNiaWdmLXJtbmtma2cxWk9SZDl4aFJUUzY1ZVVCcDJoUHZiQkhvck8tTE9Tcm1XSVhuTXNIVFBCaENzT1dYWm1RS1lLN3Vmb01zcGhGQjBvcDEwek05cWFxcHJaWHZxNDlfMnVHRDRPWTROckJZUzJrVUtJMHhVd0tMMGkyRU9UNWNGa1lKTGpheTlSd1lER3FheTBqZ1ZYZ2c1RVdFSHliOTBnckxoVVd2ci1HRE1RZW1KRGxseU9qX2VIbHA5bUZHQTEtbnRCdWVoY2JrZE83Mk9SYk1FaGhPVDJiQnhhTEk3VkpDZTNvRFFZb2FNendIMlR0QkpRZHJFUFdn?oc=5","date":"2025-11-18","type":"pipeline","source":"PR Newswire","summary":"Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight - PR Newswire","headline":"Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population an","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-12-13","type":"pipeline","source":"Pulse 2.0","summary":"Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases - Pulse 2.0","headline":"Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNU0xQWmFuZWo3R0stTldtQXRra21XZHV2WWZ2LVNubHFYdDlQNUQxUTNwdWtiNnE3Wmt5YmlNdTdJTXp1SHdoSUk3cFpKUHJJakRRLVlkdXIzeU1tSlhUb0ZIbzRfRnM2R1dQbnM0bWRpZzNfZ2hlMnJwNGwybU5id1VNRjlpZHl5WGdEUWl0SFhMdw?oc=5","date":"2024-12-13","type":"pipeline","source":"pharmaphorum","summary":"Carlyle backs Essential refinancing and other funding news - pharmaphorum","headline":"Carlyle backs Essential refinancing and other funding news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQbHItTGp6VWxOQlZyUHpTby1qaUdsd3dFWTVhNDZGd0QyOU54WXJURzB5SDh1aWtLY1h2cERRRURGNnlINjRzcWRXWllZdUNFVnZGY3hJVmZmMEpoNS1uSUIyT2Nlb2gyMkJtSF80MEFLbENVM1JDV1pVci1aa2lSbFNrSWRSRFFHTWg3aVBDRkw4LXNCNjVTaDFUWnltTnFV?oc=5","date":"2024-12-11","type":"trial","source":"Fierce Biotech","summary":"Angitia raises $120M series C to fund trio of musculoskeletal trials - Fierce Biotech","headline":"Angitia raises $120M series C to fund trio of musculoskeletal trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5EZWtMbjE2bVpsS0V4NXZ2Mlk3R0dnUzFUZ0ZDS0NDbGpuNUtwWWhEV3hxWHROWVRtLVN0dXI2OExRNUhrQjNjM3pHYzd2UWE4Q21QNDZyV2JVbE9iRjYtX1hwNEpMaXQwQmZ3cnNZcWFxa1hV?oc=5","date":"2024-11-05","type":"trial","source":"Clinical Trials Arena","summary":"Angitia doses first subject in Phase II trial of AGA2118 for treating osteoporosis - Clinical Trials Arena","headline":"Angitia doses first subject in Phase II trial of AGA2118 for treating osteoporosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQQzlyQzdvMk9hU0hPWGNDRWFKRlY5dDBFaTVfZUVodFhfSXY2XzQzOUVTLW1uT29Val9TSWNUMXo1djRLM0JpXzBveW1aVWZVSmR0U0JSVGZKcHlsRXV6dnduYXpMVUJTOTFNRWhZaUcyazMzblhpWnIwdVVuVE5KTWs4RkFfSmlncXQ4c0N6NFRXSTVPczdDRlNTOVFLOVNIdjdr?oc=5","date":"2023-10-27","type":"pipeline","source":"BioWorld News","summary":"Angitia advancing musculoskeletal pipeline with $46M series B - BioWorld News","headline":"Angitia advancing musculoskeletal pipeline with $46M series B","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-06-22","type":"pipeline","source":"PR Newswire","summary":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis, Amgen, USB, Jiangsu HengRui Medicine, Shanghai JMT-Bio, Eli Lilly and Company, ","headline":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis,","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}